Bavarian Nordic A/S
159 articles with Bavarian Nordic A/S
Bavarian Nordic A/S announced that the Company was recently engaged by Public Health England and the Medicines and Health Products Regulatory Agency to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK.
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert® in the U.S. Supported by a U.S. Commercial Team
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert ® in the U.S. Supported by a U.S. Commercial Team MORRISVILLE, N.C.--( BUSINESS WIRE )-- Bavarian Nordic today announced the initiation of full commercial operations in the U.S. only eight months after completing the acquisition of the manufacturing and global rights to Rabipur ® /RabAvert ® (Rabies Vaccine) and Encepur ® (Tick-Borne Encephalitis Vaccine) from GlaxoSmithKline p
Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature Communications
A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform was published in the prominent, peer-reviewed, open access journal, Nature Communications.
The vaccine is the only approved non-replicating smallpox vaccine in the U.S. and the only approved monkeypox vaccine anywhere in the world, the company said.
Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration has approved JYNNEOS™ for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
6/20/2019Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.
Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
Bavarian Nordic A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for the liquid-frozen version of the MVA-BN®for active immunization against smallpox in adults age 18 years and older.
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, Or...
In this randomized, open-label study of 440 volunteers, the peak neutralizing antibodies induced by IMVAMUNE were shown to be 2-fold higher than those stimulated by ACAM2000.
The planned transition will take place within 2018 once an appropriate candidate has been identified.
Bavarian Nordic Announces Initiation of Clinical Trial With Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
The trial will enroll up to 10 patients with metastatic or unresectable, locally advanced malignant solid tumors.
The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others.
Bavarian Nordic Announces Exercise of Clinical Option by the U.S. Government Under Contract for Freeze-Dried IMVAMUNE Smallpox Vaccine
Award of approximately USD 37 million will support clinical work required for product approval.
This study is designed to help determine whether a single shot administration of vaccine is required annually, or if it remains effective over multiple seasons.
Bavarian Nordic Secures Contract Award For Supply Of Freeze-Dried IMVAMUNE Smallpox Vaccine To The U.S. Government